The European Commission granted accelerated approval for EUSA Pharma’s anti-GD2 monoclonal antibody dinutuxumab beta as a treatment for children aged over 12 months with high-risk neuroblastoma. The drug was originally developed by Austrian...
EUSA Pharma, a newly-established specialty pharmaceutical business, and AVEO Oncology (NASDAQ: AVEO) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for tivozanib for the first-line...
• AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) has announced a partnership with
exclusive European rights to
• The deal could reportedly generate nearly $400 million for
AVEO Oncology has granted EUSA Pharma European rights to tivozanib for advanced renal cell carcinoma (RCC), the companies said today, in a deal that could generate up to $396.5 million-plus for AVEO.
The deal includes additional territories...
AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma, a newly-established specialty pharmaceutical business with global reach, today announced an exclusive license agreement in which AVEO has granted EUSA Pharma European rights to tivozanib for the...